AbbVie reported that its Skyrizi-based combination therapy ABBV-466 outperformed Skyrizi alone in a mid-stage Crohn’s disease trial. The company positioned the result as evidence that its IL-23 anchor can be improved through combination strategy in patients who need deeper or more durable disease control. ABBV-466 combines Skyrizi with an additional agent, with AbbVie presenting comparative efficacy against monotherapy in the study setting described. The data add to the intensifying competition in Crohn’s disease, where IL-23 inhibitors are pushing toward earlier-line use. Next steps will center on the robustness of response endpoints across patient subgroups and the durability signals needed to support escalation to later-stage development.